The Prostate Cancer Foundation Announces 2004 Coffey Award Recipients at 11th Annual Scientific Retreat
SANTA MONICA, Calif., Oct. 25 -- The Prostate Cancer Foundation today announced the recipients of the 2004 Donald S. Coffey-Prostate Cancer Foundation Physician-Scientist Awards during its 11th annual Scientific Retreat in Lake Tahoe, NV. The Donald Coffey-Prostate Cancer Foundation Physician-Scientist Awards are designed to honor Dr. Coffey's decades-long commitment to prostate cancer research and his recognition of the important role physician-scientists play in research. The four awardees were chosen for their compassionate and expert care of prostate cancer patients and excellent laboratory research that moved the field forward in a significant way. The PCF recognizes the role that Dr. Coffey and the four awardees have played in improving the lives of all men affected by prostate cancer.
This year's award recipients are:
Angelo M. DeMarzo, M.D., Ph.D. is an Associate Professor at the Johns Hopkins University School of Medicine. Dr. DeMarzo is being acknowledged for his outstanding contribution to the discovery that inflammation may cause the initiation of prostate cancer.
Martin E. Gleave, M.D., is the Chief Scientific Officer at OncoGenex. Dr. Gleave is a leading cell biologist and has defined a molecule called Clustrin as a target for the treatment of advanced prostate cancer.
Christopher Rose, M.D., FACR, is a board certified Radiation Oncologist practicing at Providence St. Joseph's Medical Center in Burbank, CA. Dr. Rose is both the Technical and Associate Director of Valley Radiotherapy Associates Medical Group. Dr. Rose is a leading investigator for the American Society for Therapeutic Radiation and Oncology (ASTRO) which has lead to optimal radiation treatments for prostate cancer.
Howard I. Scher, M.D., is Chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering. Dr. Scher has led the effort in optimizing clinical research for recurrent prostate cancer.
Leslie D. Michelson, the Prostate Cancer Foundation's vice chairman and chief executive officer, commented, "Each year, the Foundation's Retreat gathers the country's leading researchers developing new therapies designed to treat and cure prostate cancer. During this forum, we believe it is important to recognize physicians who have contributed greatly to advancing this cause and addressing a disease that affects millions of American families."
The Prostate Cancer Foundation Scientific Retreat has become the most important international scientific conference for prostate cancer. The conference gathers the most highly regarded scientific thought leaders in prostate cancer research for three days of scientific presentations, poster sessions and intense dialogue regarding clinical data, new discoveries, emerging treatment strategies and policies to accelerate drug discovery and development.
Sponsors of the Scientific Retreat include Aventis, Abbott Laboratories, Novartis, Bristol-Myers Squibb Company, OSI Pharmaceuticals, Millennium Pharmaceuticals and Sanofi.
About the Prostate Cancer Foundation
The Prostate Cancer Foundation is the world's largest philanthropic source of support for research into better treatments and a cure for prostate cancer. Founded in 1993, the PCF has raised more than $210 million and provided funding for prostate cancer research to more than 1,100 researchers at 100 institutions worldwide. For more information, visit http://www.prostatecancerfoundation.org.
Contacts: Erika Beck, Director of Communications, Prostate Cancer Foundation,
310-570-4705, or, Justin Jackson of Burns McClellan, 212-213-0006, jjackson@burnsmc.com
| 
